首页工具

搜索结果

Search Results for " pf-06651600 "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T5382	Ritlecitinib PF-06651600	JAK	Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells
	Ritlecitinib (PF-06651600) 是一种口服有效的选择性JAK3抑制剂，IC50值为 33.1 nM。
T5382L	PF-06651600 malonate PF 06651600,PF-06651600,PF06651600
	PF-06651600 is a potent and selective JAK3 inhibitor.
T69821	AMP423
	AMP423 is a naphthyl derivative of 2-cyanoaziridine-1-carboxamide with structural similarity to the pro-oxidant anti-tumor agent imexon. AMP423 was active in SCID mice bearing 8226/S myeloma and SU-DHL-6 B-cell lymphoma tumors, with a median tumor growth delay (T-C) of 21 days (P = 0.0002) and 5 days (P = 0.004), respectively, and a median tumor growth inhibition (T/C) of 33.3% (P = 0.03) and 82% (P = 0.01), respectively. In non-tumor-bearing mice, AMP423 was not myelosuppressive.
T69822	Ritlecitinib tosylate
	Ritlecitinib, also known as PF-06651600, is a potent and selective JAK3 inhibitor. PF-06651600 is a potent and low clearance compound with demonstrated in vivo efficacy. The favorable efficacy and safety profile of this JAK3-specific inhibitor PF-06651600 led to its evaluation in several human clinical studies. JAK3 was among the first of the JAKs targeted for therapeutic intervention due to the strong validation provided by human SCID patients displaying JAK3 deficiencies.
T60565	(2R,5S)-Ritlecitinib
	(2R,5S)-Ritlecitinib (2R,5S)-PF-06651600) 是有效的选择性 JAK3抑制剂，IC50 值为144.8 nM。